neratinib (Nerlynx)

From Aaushi
Jump to navigation Jump to search

Indications

Dosage

Tabs: 40 mg

Adverse effects

Mechanism of action

More general terms

Additional terms

References

  1. Jump up to: 1.0 1.1 Burstein HJ et al Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. J Clin Oncol March 10, 2010 vol. 28 no. 8 1301-1307 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20142587 <Internet> http://jco.ascopubs.org/content/28/8/1301
  2. Gradishar WJ Neratinib for Metastatic HER2 Breast Cancer. NEJM Journal Watch. Nov 3, 2014 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
    Saura C et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2014 Oct 6 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25287822 <Internet> http://jco.ascopubs.org/content/early/2014/10/03/JCO.2014.56.3809
  3. FDA Briefing Document. May 24, 2017 Oncologic Drugs Advisory Committee Meeting NDA 208051. Neratinib. Applicant: Puma Biotechnology, Inc https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559721.pdf
  4. Jump up to: 4.0 4.1 4.2 4.3 FDA News Release. July 17, 2017 FDA approves new treatment to reduce the risk of breast cancer returning. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567309.htm
    Windle ML. FDA New Drug and Biologic Approvals -- 2017 Year-in-Review Medscape - Jan 11, 2018. https://reference.medscape.com/viewarticle/890871
    U.S. Food and Drug Administration. Novel Drug Approvals for 2017. https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm537040.htm
  5. Chan A, Delaloge S, Holmes FA et al Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016 Mar;17(3):367-77. Epub 2016 Feb 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/26874901